ahajournals.org6d
Abstract 4133122: Integrative Metabolomic Analysis of Triglyceride-Independent Lipoprotein Lipase Pathway Mechanisms for Coronary Artery Disease
Background: Strong genetic evidence supports the associations between key genes in triglyceride (TG) metabolism via the lipoprotein lipase (LPL) pathway (i.e., LPL, APOC3, and ANGPTL3) and coronary ...
pharmaphorum1d
Submission completed, Spark sets sight on first ever US gene therapy approval
Glybera is a case study in the pitfalls of pioneering gene therapy: the lipoprotein lipase deficiency (LPLD) treatment is to be withdrawn from the market after proving to be a huge commercial failure.
pharmaphorum2d
Opportunity costs of gene therapies. Where do we go from here?
UniQuire’s Glybera (alipogene tiparvovec) was withdrawn from the European market five years after it was approved to treat familial lipoprotein lipase deficiency (LPLD). More recently, ...